{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:10:12Z","timestamp":1789153812683,"version":"build-2803163510"},"reference-count":127,"publisher":"Society of Nuclear Medicine","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.2967\/jnumed.125.269488","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:40:16Z","timestamp":1789152016000},"page":"60S-78S","source":"Crossref","is-referenced-by-count":0,"title":["Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities"],"prefix":"10.2967","volume":"67","author":[{"given":"Richard L.","family":"Wahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuni K.","family":"Dewaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091111400918000_67.Supplement_2.60S.1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/sonc.2003.23799","article-title":"The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab","volume":"30","author":"Wahl","year":"2003","journal-title":"Semin Oncol."},{"key":"2026091111400918000_67.Supplement_2.60S.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308123290703"},{"key":"2026091111400918000_67.Supplement_2.60S.3","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","article-title":"Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma","volume":"14","author":"Kaminski","year":"1996","journal-title":"J Clin Oncol."},{"key":"2026091111400918000_67.Supplement_2.60S.4","first-page":"128S","article-title":"Tositumomab and 131I therapy in non-Hodgkin\u2019s lymphoma","volume":"46(suppl 1)","author":"Wahl","year":"2005","journal-title":"J Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"2026091111400918000_67.Supplement_2.60S.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.073155"},{"key":"2026091111400918000_67.Supplement_2.60S.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"2026091111400918000_67.Supplement_2.60S.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.043489"},{"key":"2026091111400918000_67.Supplement_2.60S.9","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.3390\/cancers13112828","article-title":"Prospective SPECT-CT organ dosimetry-driven radiation-absorbed dose escalation using the In-111 (111In)\/yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) theranostic pair in patients with lymphoma at myeloablative dose levels","volume":"13","author":"Wahl","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026091111400918000_67.Supplement_2.60S.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026091111400918000_67.Supplement_2.60S.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.08.075"},{"key":"2026091111400918000_67.Supplement_2.60S.12","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.2967\/jnumed.121.262751","article-title":"Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns","volume":"62(suppl 3)","author":"Wahl","year":"2021","journal-title":"J Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.09.040"},{"key":"2026091111400918000_67.Supplement_2.60S.14","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1002\/mp.13092","article-title":"A dosimetric evaluation of the IAEA\u2010AAPM TRS 483 code of practice for dosimetry of small static fields used in conventional linac beams and comparison with IAEA TRS\u2010398, AAPM TG 51, and TG 51 addendum protocols","volume":"9","author":"Huq","year":"2018","journal-title":"Med Phys."},{"key":"2026091111400918000_67.Supplement_2.60S.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.02.045"},{"key":"2026091111400918000_67.Supplement_2.60S.16","first-page":">CD012817","article-title":"Dose\u2010escalated radiotherapy for clinically localized and locally advanced prostate cancer","volume":"3","author":"Lee","year":"2023","journal-title":"Cochrane Database Syst Rev."},{"key":"2026091111400918000_67.Supplement_2.60S.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03697"},{"key":"2026091111400918000_67.Supplement_2.60S.18","doi-asserted-by":"crossref","first-page":"103432","DOI":"10.1016\/j.eclinm.2025.103432","article-title":"Radiation dose escalation in locally advanced oesophageal cancer: a systematic review and hierarchical Bayesian meta-analysis","volume":"87","author":"Dai","year":"2025","journal-title":"EClinicalMedicine."},{"key":"2026091111400918000_67.Supplement_2.60S.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30742-7"},{"key":"2026091111400918000_67.Supplement_2.60S.20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S2213-2600(24)00189-9","article-title":"High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial","volume":"12","author":"Yu","year":"2024","journal-title":"Lancet Respir Med."},{"key":"2026091111400918000_67.Supplement_2.60S.21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cam4.1948","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: practice patterns, dose selection and factors impacting survival","volume":"8","author":"Robbins","year":"2019","journal-title":"Cancer Med."},{"key":"2026091111400918000_67.Supplement_2.60S.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.03.045"},{"key":"2026091111400918000_67.Supplement_2.60S.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01162"},{"key":"2026091111400918000_67.Supplement_2.60S.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71207-0"},{"key":"2026091111400918000_67.Supplement_2.60S.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267452"},{"key":"2026091111400918000_67.Supplement_2.60S.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05727-7"},{"key":"2026091111400918000_67.Supplement_2.60S.27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/10507256251396454","article-title":"A systematic review of absorbed doses and response in patients treated with radioiodine for differentiated thyroid cancer","volume":"36","author":"Taprogge","year":"2026","journal-title":"Thyroid."},{"key":"2026091111400918000_67.Supplement_2.60S.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2824-5"},{"key":"2026091111400918000_67.Supplement_2.60S.29","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to 90Y-and 177Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","author":"Cremonesi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.30","first-page":"12S","article-title":"Tumor response to radiopharmaceutical therapies: the knowns and the unknowns","volume":"62(suppl 3)","author":"Sgouros","year":"2021","journal-title":"J Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.168799"},{"key":"2026091111400918000_67.Supplement_2.60S.32","first-page":"457","article-title":"Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients","volume":"44","author":"Koral","year":"2003","journal-title":"J Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.136044"},{"key":"2026091111400918000_67.Supplement_2.60S.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.271039"},{"key":"2026091111400918000_67.Supplement_2.60S.35","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ijrobp.2025.06.3869","article-title":"177Lu-PSMA-617 single-photon emission computed tomography\/computed tomography dosimetry and radiobiological models demonstrate decreasing tumor-to-kidney dose ratio with successive cycles","volume":"123","author":"Fitzpatrick","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2026091111400918000_67.Supplement_2.60S.36","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2026091111400918000_67.Supplement_2.60S.37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270170"},{"key":"2026091111400918000_67.Supplement_2.60S.38","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269377"},{"key":"2026091111400918000_67.Supplement_2.60S.39","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1007\/s00259-021-05340-0","article-title":"To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer","volume":"48","author":"Roosen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.40","doi-asserted-by":"crossref","first-page":"245010","DOI":"10.1088\/1361-6560\/aaf205","article-title":"90Y TOF-PET based EUD reunifies patient survival prediction in resin and glass microspheres radioembolization of HCC tumours","volume":"63","author":"d\u2019Abadie","year":"2018","journal-title":"Phys Med Biol."},{"key":"2026091111400918000_67.Supplement_2.60S.41","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","article-title":"EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds","volume":"49","author":"Weber","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266211"},{"key":"2026091111400918000_67.Supplement_2.60S.43","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0778-1"},{"key":"2026091111400918000_67.Supplement_2.60S.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01241"},{"key":"2026091111400918000_67.Supplement_2.60S.45","first-page":"99S","article-title":"Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose\u2013effect relationship","volume":"46(suppl 1)","author":"Barone","year":"2005","journal-title":"J Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.46","doi-asserted-by":"crossref","first-page":"1716247","DOI":"10.3389\/fendo.2025.1716247","article-title":"Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial","volume":"16","author":"Kolodziej","year":"2025","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2026091111400918000_67.Supplement_2.60S.47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268903"},{"key":"2026091111400918000_67.Supplement_2.60S.48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2026091111400918000_67.Supplement_2.60S.49","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269389"},{"key":"2026091111400918000_67.Supplement_2.60S.50","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265986"},{"key":"2026091111400918000_67.Supplement_2.60S.51","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13550-019-0548-z","article-title":"3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT\/CT","volume":"9","author":"Gosewisch","year":"2019","journal-title":"EJNMMI Res."},{"key":"2026091111400918000_67.Supplement_2.60S.52","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.225235"},{"key":"2026091111400918000_67.Supplement_2.60S.53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-025-00816-6","article-title":"Comparison of imaging-based bone marrow dosimetry methodologies and their dose\u2013effect relationships in [177Lu] Lu-PSMA-617 RLT including a novel method with active marrow localization","volume":"13","author":"Peterson","year":"2025","journal-title":"EJNMMI Phys."},{"key":"2026091111400918000_67.Supplement_2.60S.54","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266843"},{"key":"2026091111400918000_67.Supplement_2.60S.55","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2008.05.003"},{"key":"2026091111400918000_67.Supplement_2.60S.56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12967-023-03991-1","article-title":"Large-scale in\u00a0vitro microdosimetry via live cell microscopy imaging: implications for radiosensitivity and RBE evaluations in alpha-emitter radiopharmaceutical therapy","volume":"21","author":"Bastiaannet","year":"2023","journal-title":"J Transl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.57","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/41\/10\/001"},{"key":"2026091111400918000_67.Supplement_2.60S.58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/14736691211060117","article-title":"ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy","volume":"21","author":"Sgouros","year":"2021","journal-title":"J ICRU."},{"key":"2026091111400918000_67.Supplement_2.60S.59","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/RLU.0000000000006302","article-title":"Assessing PSMA receptor availability using Ga-86-PSMA-11 PET\/CT following Lu-177-PSMA-617 therapy administration","volume":"51","author":"Roseland","year":"2026","journal-title":"Clin Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13550-026-01417-9","article-title":"Fractionation gives therapeutic benefit in animal model of [177Lu] Lu-PSMA-617 therapy of prostate cancer","volume":"16","author":"Timmermand","year":"2026","journal-title":"EJNMMI Res."},{"key":"2026091111400918000_67.Supplement_2.60S.61","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s11307-021-01600-5","article-title":"Prospective within-patient assessment of the impact of an unlabeled octreotide pre-dose on the biodistribution and tumor uptake of 68Ga DOTATOC as assessed by dynamic whole-body PET in patients with neuroendocrine tumors: implications for diagnosis and therapy","volume":"23","author":"Lodge","year":"2021","journal-title":"Mol Imaging Biol."},{"key":"2026091111400918000_67.Supplement_2.60S.62","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262069"},{"key":"2026091111400918000_67.Supplement_2.60S.63","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266991"},{"key":"2026091111400918000_67.Supplement_2.60S.64","doi-asserted-by":"crossref","unstructured":"Bailey DL Dickson JC Lapi SE . Pulling together: a 5-year plan to improve theranostic outcomes by improving the accuracy of dosimetry\u2014an FNIH joint academic, clinical, and industrial collaboration. J Nucl Med. April 2, 2026 [Epub ahead of print].","DOI":"10.2967\/jnumed.125.271665"},{"key":"2026091111400918000_67.Supplement_2.60S.65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40658-021-00397-0","article-title":"A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT\/CT imaging performed within the MRTDosimetry project","volume":"8","author":"Tran-Gia","year":"2021","journal-title":"EJNMMI Phys."},{"key":"2026091111400918000_67.Supplement_2.60S.66","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1007\/s00259-025-07313-z","article-title":"Organ and tumour dosimetry of 177Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a phase I trial","volume":"52","author":"Nagarajah","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.67","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264953"},{"key":"2026091111400918000_67.Supplement_2.60S.68","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40658-022-00436-4","article-title":"Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu] Lu-DOTATATE","volume":"9","author":"Malcolm","year":"2022","journal-title":"EJNMMI Phys."},{"key":"2026091111400918000_67.Supplement_2.60S.69","doi-asserted-by":"crossref","first-page":"36S","DOI":"10.2967\/jnumed.121.262748","article-title":"An international study of factors affecting variability of dosimetry calculations, part 1: design and early results of the SNMMI Dosimetry Challenge","volume":"62(suppl 3)","author":"Uribe","year":"2021","journal-title":"J Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.70","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269378"},{"key":"2026091111400918000_67.Supplement_2.60S.71","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40658-024-00658-8","article-title":"A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?","volume":"11","author":"Vergnaud","year":"2024","journal-title":"EJNMMI Phys."},{"key":"2026091111400918000_67.Supplement_2.60S.72","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264594"},{"key":"2026091111400918000_67.Supplement_2.60S.73","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.3390\/cancers13153884","article-title":"Streamlined schemes for dosimetry of 177Lu-labeled PSMA targeting radioligands in therapy of prostate cancer","volume":"13","author":"Kurth","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026091111400918000_67.Supplement_2.60S.74","doi-asserted-by":"crossref","first-page":"e230024","DOI":"10.1148\/ryai.230024","article-title":"TotalSegmentator: robust segmentation of 104 anatomic structures in CT images","volume":"5","author":"Wasserthal","year":"2023","journal-title":"Radiol Artif Intell."},{"key":"2026091111400918000_67.Supplement_2.60S.75","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264225"},{"key":"2026091111400918000_67.Supplement_2.60S.76","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.2967\/jnumed.121.262749","article-title":"Dosimetry for radiopharmaceutical therapy: current practices and commercial resources","volume":"62(suppl 3)","author":"Capala","year":"2021","journal-title":"J Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.77","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263738"},{"key":"2026091111400918000_67.Supplement_2.60S.78","unstructured":"Bartlett RM Bolch WE Brill AB Woodruffe P . MIRD Primer 2022: A Complete Guide to Radiopharmaceutical Dosimetry. Society of Nuclear Medicine; 2022."},{"key":"2026091111400918000_67.Supplement_2.60S.79","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.269539"},{"key":"2026091111400918000_67.Supplement_2.60S.80","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1007\/s00259-022-05883-w","article-title":"Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy","volume":"49","author":"Xue","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.81","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ijrobp.2025.05.014","article-title":"Machine learning-based dose prediction in [177Lu] Lu-PSMA-617 therapy by integrating biomarkers and radiomic features from [68Ga] Ga-PSMA-11 PET\/CT","volume":"123","author":"Yazdani","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2026091111400918000_67.Supplement_2.60S.82","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06252-x"},{"key":"2026091111400918000_67.Supplement_2.60S.83","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/RLU.0000000000004599","article-title":"177Lu-DOTATATE theranostics: predicting renal dosimetry from pretherapy 68Ga-DOTATATE PET and clinical biomarkers","volume":"48","author":"Peterson","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.84","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269098"},{"key":"2026091111400918000_67.Supplement_2.60S.85","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270872"},{"key":"2026091111400918000_67.Supplement_2.60S.86","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00605-2"},{"key":"2026091111400918000_67.Supplement_2.60S.87","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267723"},{"key":"2026091111400918000_67.Supplement_2.60S.88","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu] Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.89","doi-asserted-by":"crossref","first-page":"1559\u20131569","DOI":"10.1007\/s00259-025-07541-3","article-title":"Effect of bone marrow disease on hematologic toxicity and response to [177Lu] Lu-PSMA-617 therapy: insights from PSMA-PET\/CT imaging","volume":"53","author":"Borges","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.90","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264677"},{"key":"2026091111400918000_67.Supplement_2.60S.91","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267606"},{"key":"2026091111400918000_67.Supplement_2.60S.92","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267208"},{"key":"2026091111400918000_67.Supplement_2.60S.93","doi-asserted-by":"crossref","first-page":"1913\u20131926","DOI":"10.1007\/s00259-025-07628-x","article-title":"Fully automated volumetric assessment of tumor burden using artificial intelligence on 68Ga-PSMA-11 PET predicts survival after 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer","volume":"53","author":"Zang","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.94","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.95","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","article-title":"Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients","volume":"49","author":"Sundl\u00f6v","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.96","doi-asserted-by":"crossref","first-page":"101743","DOI":"10.1016\/j.adro.2025.101743","article-title":"Sequential 90Y selective internal radiation therapy (SIRT) and stereotactic body radiation therapy (SBRT) using 90Y PET-based absorbed dose maps: interim analysis of a phase 1 study","volume":"10","author":"Polan","year":"2025","journal-title":"Adv Radiat Oncol."},{"key":"2026091111400918000_67.Supplement_2.60S.97","unstructured":"PLUVICTO\u00ae (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use. Novartis website. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/pluvicto.pdf. Published 2025. Accessed July 10, 2026."},{"key":"2026091111400918000_67.Supplement_2.60S.98","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s00259-024-06681-2","article-title":"Image-based dosimetry for [225Ac] Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics","volume":"51","author":"Liubchenko","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.99","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"2026091111400918000_67.Supplement_2.60S.100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.semnuclmed.2019.11.002","article-title":"Dosimetry, radiobiology and synthetic lethality: radiopharmaceutical therapy (RPT) with alpha-particle-emitters","volume":"50","author":"Sgouros","year":"2020","journal-title":"Semin Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.101","doi-asserted-by":"crossref","unstructured":"Gabi\u00f1a PM Gleisner KS Chouin N . EANM dosimetry committee recommendations for dosimetry in targeted radionuclide therapy with alpha-emitters. EANM Innovation. 2026:100018.","DOI":"10.1016\/j.eanmi.2025.100018"},{"key":"2026091111400918000_67.Supplement_2.60S.102","doi-asserted-by":"crossref","first-page":"4446\u20134459","DOI":"10.1007\/s00259-025-07754-6","article-title":"First-in-human evaluation of [211At] YF2 in patients with metastatic castration-resistant prostate cancer","volume":"53","author":"Wu","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.103","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270810"},{"key":"2026091111400918000_67.Supplement_2.60S.104","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270654"},{"key":"2026091111400918000_67.Supplement_2.60S.105","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1007\/s00259-024-07009-w","article-title":"First-in-human administration of [161Tb] Tb-SibuDAB and comparative dosimetry with standard [177Lu] Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study","volume":"52","author":"Chirindel","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.106","doi-asserted-by":"publisher","DOI":"10.1093\/rpd\/ncu285"},{"key":"2026091111400918000_67.Supplement_2.60S.107","doi-asserted-by":"publisher","DOI":"10.1093\/rpd\/ncv031"},{"key":"2026091111400918000_67.Supplement_2.60S.108","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-020-05038-9","article-title":"EANM position paper on article 56 of the council directive 2013\/59\/Euratom (basic safety standards) for nuclear medicine therapy","volume":"48","author":"Konijnenberg","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.109","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270979"},{"key":"2026091111400918000_67.Supplement_2.60S.110","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.271268"},{"key":"2026091111400918000_67.Supplement_2.60S.111","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.253443"},{"key":"2026091111400918000_67.Supplement_2.60S.112","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.117952"},{"key":"2026091111400918000_67.Supplement_2.60S.113","first-page":"2025","article-title":"To AC or not to AC: that is the question","volume":"40","author":"Wahl","year":"1999","journal-title":"J Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.114","first-page":"1369","article-title":"A combined PET\/CT scanner for clinical oncology","volume":"41","author":"Beyer","year":"2000","journal-title":"J Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.115","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5631"},{"key":"2026091111400918000_67.Supplement_2.60S.116","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.245548"},{"key":"2026091111400918000_67.Supplement_2.60S.117","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40658-025-00762-3","article-title":"Shorter SPECT scans using self-supervised coordinate learning to synthesize skipped projection views","volume":"12","author":"Li","year":"2025","journal-title":"EJNMMI Phys."},{"key":"2026091111400918000_67.Supplement_2.60S.118","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/jso.25748","article-title":"The radiation dose\u2010response of non\u2010retroperitoneal soft tissue sarcoma with positive margins: an NCDB analysis","volume":"120","author":"Wells","year":"2019","journal-title":"J Surg Oncol."},{"key":"2026091111400918000_67.Supplement_2.60S.119","doi-asserted-by":"crossref","first-page":"498","DOI":"10.6004\/jnccn.2025.0058","article-title":"NCCN Guidelines\u00ae insights: soft tissue sarcoma, version 1.2025\u2014featured updates to the NCCN guidelines","volume":"23","author":"von Mehren","year":"2025","journal-title":"J Natl Compr Canc Netw."},{"key":"2026091111400918000_67.Supplement_2.60S.120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clon.2019.12.004","article-title":"A review of modern radiation therapy dose escalation in locally advanced head and neck cancer","volume":"32","author":"Atwell","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"2026091111400918000_67.Supplement_2.60S.121","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267023"},{"key":"2026091111400918000_67.Supplement_2.60S.122","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265987"},{"key":"2026091111400918000_67.Supplement_2.60S.123","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00259-024-06863-y","article-title":"The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu] Lu-DOTATATE","volume":"52","author":"Maccauro","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.124","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin Nucl Med."},{"key":"2026091111400918000_67.Supplement_2.60S.125","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00259-021-05471-4","article-title":"Intra-therapeutic dosimetry of [177Lu] Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome","volume":"49","author":"Peters","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400918000_67.Supplement_2.60S.126","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/diagnostics11030428","article-title":"Correlation of an index-lesion-based SPECT dosimetry method with mean tumor dose and clinical outcome after 177Lu-PSMA-617 radioligand therapy","volume":"11","author":"V\u00f6lter","year":"2021","journal-title":"Diagnostics (Basel)."},{"key":"2026091111400918000_67.Supplement_2.60S.127","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40644-022-00505-y","article-title":"Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer","volume":"22","author":"Beauregard","year":"2022","journal-title":"Cancer Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:41:16Z","timestamp":1789152076000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":127,"journal-issue":{"issue":"Supplement 2","published-online":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.2967\/jnumed.125.269488"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269488","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}